INTERNATIONAL MULTICENTER STUDY, DOUBLE-BLIND, RANDOMIZED, PHASE III OF SATRAPLATIN PLUSBO PLUSBO OR PREDNISONE PLUSBO IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER PREVIOUSLY TREATED WITH A REGIME OF CYTOXIC CHEMOTHERAPY GPC SAT3-03-01
Not Applicable
Completed
- Conditions
- -C61 Malignant neoplasm of prostateMalignant neoplasm of prostateC61
- Registration Number
- PER-001-04
- Lead Sponsor
- GPC BIOTECH INC.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Metastatic prostate cancer in stage D2
Progression after previous chemotherapy
ECOG performance status equal / less than 2
Life expectancy> 3 months
Surgical or medical castration
Adequate functions of bone marrow, liver and kidney
Informed consent
Exclusion Criteria
More than one prior chemotherapy
Previous compounds containing platinum
Previous malignancy
Previous RT / radionuclide therapy
Major surgery GI or GI disease that affects absorption
Disease with contraindication for steroids
Brain metastasis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br>Outcome name:not contemplated<br>Measure:not contemplated<br>Timepoints:not contemplated<br>
- Secondary Outcome Measures
Name Time Method <br>Outcome name:not contemplated<br>Measure:not contemplated<br>Timepoints:not contemplated<br>